A new study reveals how C210, a curcumin derivative, selectively reactivates Epstein–Barr virus to kill cancer cells without infectious risks, paving the way for safer, targeted cancer therapies.
Researchers at the Wistar Institute and their collaborators say they have discovered a potential target for gastric cancers associated with Epstein-Barr Virus. The study “Decitabine disrupts EBV ...
Francesca has an MSci in Biochemistry from the University of Birmingham.View full profile Francesca has an MSci in Biochemistry from the University of Birmingham. Epstein-Barr Virus (EBV) is very ...
PHILADELPHIA—(August 22, 2023)—Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback